BioStock: BioInvent sums up eventful Q2

BioInvent’s report for the second quarter of 2022 breeds confidence. The Swedish pharmaceutical company entered into an option and license agreement with US based Exelixis, with an advance payment to BioInvent of 25 MUSD. During the period, the company also reported progress in its clinical projects, which now span five clinical programmes and a total of four drug candidates. In addition, the company strengthened its cash position by close to 300 million SEK through a directed share issue to foreign and Swedish investors, despite the turbulent global financial situation.

Read the article at biostock.se:

https://www.biostock.se/en/2022/08/bioinvent-sums-up-eventful-q2/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/